A New Approach to the Biology of Aging and Disease.
One Biological Mechanism. Multiple Therapeutic Frontiers.
Senescent cell accumulation is a key driver of aging, disrupting tissue function and promoting inflammation. Because aging is slow and not yet a defined regulatory indication, we are advancing our lead compound, SNC711, toward IND in oncology, where disease and treatment reproduce the hallmarks of aging in a rapid timeframe.
Cellular senescence is emerging as a shared biological driver
Across metabolic disease, cancer, fibrosis, immune dysfunction and aging. Senvi is developing SNC711, a novel therapeutic peptide designed to selectively eliminate senescent cells while preserving healthy tissue.
Why Senescence Matters
As we age and in many diseases, senescent cells accumulate in tissues. Instead of being cleared, these dysfunctional cells persist and release inflammatory signals that impair immune surveillance, promote fibrosis, disrupt metabolism, accelerate tissue degeneration and contribute to treatment resistance. These diverse conditions may share a common biological driver, senescent cell accumulation, creating an opportunity for a new class of medicines with reach across multiple major therapeutic areas.
Why We Believe SNC711 Can Translate to Humans
SNC711's remarkable preclinical data supports its potential to translate to human medicine.
01
Biology that extends across species
SNC711 shows senolytic activity in human and mouse cells and in nematodes, suggesting its mechanism is shared across species rather than unique to a single animal model.
02
Safety across a wide dose range
SNC711 is effective at 10-20 mg/kg with no measurable toxicity at 125 mg/kg (6-12x higher) across 250+ mice, including 10+ weekly doses, with no meaningful blood, liver or kidney changes and no evidence of mutagenicity in preliminary Ames testing.
03
Delivery
SNC711 was chemically modified to resist breakdown and improve cell penetration, enabling both IV and oral delivery. Its 20 mg/kg effective dose in mice translates to an estimated 200 mg human dose, suitable for pill formulation and potentially avoiding the hurdles of IV delivery.
01
A platform, not a single asset
One biological mechanism with the potential for multiple therapeutic candidates across major diseases.
Biological Rejuvenation
02
Enhancement to exisiting therapies
SNC711 has the potential to make established therapies more effective and durable, creating opportunities for powerful combination therapies.
Reduced Weight
03
Multiple paths to value
A platform spanning standalone therapies, combination treatments, indication expansion and strategic partnerships.
Tumors Evade Therapy
03
The opportunity
ahead
SNC711 could define a new therapeutic category addressing some of the greatest challenges in human health, including longevity.
Tumors Evade Therapy